{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:57:36Z","timestamp":1758776256781,"version":"3.44.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T00:00:00Z","timestamp":1751068800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-025-04333-5","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T12:59:34Z","timestamp":1751115574000},"page":"208-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lenvatinib for unresectable anaplastic thyroid cancer: real-world experiences in multi-institutional study"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6206-6214","authenticated-orcid":false,"given":"Takuya","family":"Mikoshiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Sekimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeyuki","family":"Kono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoto","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoaki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiji","family":"Kawasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noboru","family":"Habu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,28]]},"reference":[{"key":"4333_CR1","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s00268-012-1437-z","volume":"36","author":"I Sugitani","year":"2012","unstructured":"I. Sugitani, A. Miyauchi, K. Sugino, T. Okamoto, A. Yoshida, S. Suzuki, Prognostic factors and treatment outcomes for anaplastic thyroid carcinoma: ATC research consortium of Japan cohort study of 677 patients. World J. Surg. 36, 1247\u20131254 (2012)","journal-title":"World J. Surg."},{"key":"4333_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"M. Tahara, N. Kiyota, T. Yamazaki, N. Chayahara, K. Nakano, L. Inagaki, K. Toda, T. Enokida, H. Minami, Y. Imamura, T. Sasaki, T. Suzuki, K. Fujino, C.E. Dutcus, S. Takahashi, Lenvatinib for anaplastic thyroid cancer. Front. Oncol. 7, 25 (2017). https:\/\/doi.org\/10.3389\/fonc.2017.00025","journal-title":"Front. Oncol."},{"key":"4333_CR3","unstructured":"NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): thyroid carcinoma, version 5 2024. (2024), https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf. Accessed 22 Feb 2025"},{"key":"4333_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"V. Subbiah, R.J. Kreitman, Z.A. Wainberg, A. Gazzah, U. Lassen, A. Stein, P.Y. Wen, S. Dietrich, M.J.A. de Jonge, J.Y. Blay, A. Italiano, K. Yonemori, D.C. Cho, F.Y.F.L. de Vos, P. Moreau, E.E. Fernandez, J.H.M. Schellens, C.C. Zielinski, S. Redhu, A. Boran, V.Q. Passos, P. Ilankumaran, Y.J. Bang, Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat. Med. 29, 1103\u20131112 (2023)","journal-title":"Nat. Med."},{"key":"4333_CR5","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12020-024-03738-y","volume":"85","author":"H Yamazaki","year":"2024","unstructured":"H. Yamazaki, C. Kunisaki, M. Sugimori, Y. Rino, A. Saito, Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan. Endocrine 85, 766\u2013776 (2024)","journal-title":"Endocrine"},{"key":"4333_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1507\/endocrj.EJ23-0342","volume":"71","author":"S Toda","year":"2024","unstructured":"S. Toda, H. Iwasaki, Y. Okubo, H. Hayashi, M. Kadoya, H. Takahashi, T. Yokose, Y. Hiroshima, K. Masudo, The frequency of mutations in advanced thyroid cancer in Japan: a single-center study. Endocr. J. 71, 31\u201337 (2024)","journal-title":"Endocr. J."},{"key":"4333_CR7","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1172\/JCI85271","volume":"126","author":"I Landa","year":"2016","unstructured":"I. Landa, T. Ibrahimpasic, L. Boucai, R. Sinha, J.A. Knauf, R.H. Shah, S. Dogan, J.C. Ricarte-Filho, G.P. Krishnamoorthy, B. Xu, N. Schultz, M.F. Berger, C. Sander, B.S. Taylor, R. Ghossein, I. Ganly, J.A. Fagin, Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J. Clin. Invest. 126, 1052\u20131066 (2016)","journal-title":"J. Clin. Invest."},{"key":"4333_CR8","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"N. Pozdeyev, L.M. Gay, E.S. Sokol, R. Hartmaier, K.E. Deaver, S. Davis, J.D. French, P.V. Borre, D.V. LaBarbera, A.C. Tan, R.E. Schweppe, L. Fishbein, J.S. Ross, B.R. Haugen, D.W. Bowles, Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res. 24, 3059\u20133068 (2018)","journal-title":"Clin. Cancer Res."},{"key":"4333_CR9","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","volume":"109","author":"S Toda","year":"2024","unstructured":"S. Toda, Y. Hiroshima, H. Iwasaki, K. Masudo, Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan. J. Clin. Endocrinol. Metab. 109, 2784\u20132792 (2024)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4333_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. de las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621\u2013630 (2015)","journal-title":"N. Engl. J. Med."},{"key":"4333_CR11","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1089\/thy.2023.0553","volume":"34","author":"M Tahara","year":"2024","unstructured":"M. Tahara, H. Takami, Y. Ito, T. Okamoto, I. Sugitani, K. Sugino, S. Takahashi, H. Takeyama, H. Tsutsui, H. Hara, A. Mitsuma, H. Yamashita, Y. Ohashi, T. Imai, A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 34, 566\u2013574 (2024)","journal-title":"Thyroid"},{"key":"4333_CR12","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s12020-024-03744-0","volume":"85","author":"T Mikoshiba","year":"2024","unstructured":"T. Mikoshiba, M. Sekimizu, T. Kono, R. Nagai, T. Kawasaki, Y. Sato, F. Ito, N. Nakahara, S. Shigetomi, H. Ozawa, Utility and optimal management of planned drug holidays during lenvatinib treatment in patients with unresectable differentiated thyroid cancer: a real-world multi-center study. Endocrine 85, 777\u2013785 (2024)","journal-title":"Endocrine"},{"key":"4333_CR13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s002680020166","volume":"25","author":"I Sugitani","year":"2001","unstructured":"I. Sugitani, N. Kasai, Y. Fujimoto, A. Yanagisawa, Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J. Surg. 25, 617\u2013622 (2001)","journal-title":"World J. Surg."},{"key":"4333_CR14","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1089\/thy.2017.0285","volume":"28","author":"PC Iyer","year":"2018","unstructured":"P.C. Iyer, R. Dadu, R. Ferrarotto, N.L. Busaidy, M.A. Habra, M. Zafereo, N. Gross, K.R. Hess, M. Gule-Monroe, M.D. Williams, M.E. Cabanillas, Real-world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28, 79\u201387 (2018)","journal-title":"Thyroid"},{"key":"4333_CR15","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.21873\/invivo.12113","volume":"34","author":"N Fukuda","year":"2020","unstructured":"N. Fukuda, K. Toda, Y.U. Fujiwara, X. Wang, A. Ohmoto, T. Urasaki, N. Hayashi, Y. Sato, K. Nakano, M. Yunokawa, M. Ono, J. Tomomatsu, H. Mitani, S. Takahashi, Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib. In Vivo 34, 2859\u20132864 (2020)","journal-title":"In Vivo"},{"key":"4333_CR16","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1007\/s12325-020-01433-8","volume":"37","author":"S Takahashi","year":"2020","unstructured":"S. Takahashi, M. Tahara, K. Ito, M. Tori, N. Kiyota, K. Yoshida, Y. Sakata, A. Yoshida, Safety and effectiveness of lenvatinib in 594 patients with unresectable thyroid cancer in an all-case post-marketing observational study in Japan. Adv. Ther. 37, 3850\u20133862 (2020)","journal-title":"Adv. Ther."},{"key":"4333_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s12020-020-02425-y","volume":"71","author":"M Kim","year":"2021","unstructured":"M. Kim, J. Ahn, D.E. Song, J.H. Yoon, H.C. Kang, D.J. Lim, W.G. Kim, T.Y. Kim, W.B. Kim, Y.K. Shong, M.J. Jeon, B.H. Kim, Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer. Endocrine 71, 427\u2013433 (2021)","journal-title":"Endocrine"},{"key":"4333_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1530\/EJE-20-1482","volume":"184","author":"J Park","year":"2021","unstructured":"J. Park, H.A. Jung, J.H. Shim, W.Y. Park, T.H. Kim, S.H. Lee, S.W. Kim, M.J. Ahn, K. Park, J.H. Chung, Multimodal treatments and outcomes for anaplastic thyroid cancer before and after tyrosine kinase inhibitor therapy: a real-world experience. Eur. J. Endocrinol. 184, 837\u2013845 (2021)","journal-title":"Eur. J. Endocrinol."},{"key":"4333_CR19","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1200\/JCO.20.03093","volume":"39","author":"LJ Wirth","year":"2021","unstructured":"L.J. Wirth, M.S. Brose, E.J. Sherman, L. Licitra, M. Schlumberger, S.I. Sherman, K.C. Bible, B. Robinson, P. Rodien, Y. Godbert, C. De La Fouchardiere, K. Newbold, C. Nutting, S. Misir, R. Xie, A. Almonte, W. Ye, M.E. Cabanillas, Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer. J. Clin. Oncol. 39, 2359\u20132366 (2021)","journal-title":"J. Clin. Oncol."},{"key":"4333_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/ERC-20-0106","volume":"28","author":"C Sparano","year":"2021","unstructured":"C. Sparano, Y. Godbert, M. Attard, C. Do Cao, S. Zerdoud, N. Roudaut, C. Joly, A. Berdelou, J. Hadoux, L. Lamartina, M. Schlumberger, S. Leboulleux, Limited efficacy of lenvatinib in heavily pretreated anaplastic thyroid cancer: a French overview. Endocr. Relat. Cancer 28, 15\u201326 (2021)","journal-title":"Endocr. Relat. Cancer"},{"key":"4333_CR21","doi-asserted-by":"publisher","first-page":"852","DOI":"10.21037\/gs-20-871","volume":"10","author":"H Yamazaki","year":"2021","unstructured":"H. Yamazaki, H. Iwasaki, N. Suganuma, S. Toda, K. Masudo, H. Nakayama, Y. Rino, M. Masuda, Inflammatory biomarkers and dynamics of neutrophil-to-lymphocyte ratio in lenvatinib treatment for anaplastic thyroid carcinoma. Gland. Surg. 10, 852\u2013860 (2021)","journal-title":"Gland. Surg."},{"key":"4333_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3892\/ol.2023.14002","volume":"26","author":"H Iwasaki","year":"2023","unstructured":"H. Iwasaki, S. Toda, A. Takahashi, K. Masudo, Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer. Oncol. Lett. 26, 416 (2023). https:\/\/doi.org\/10.3892\/ol.2023.14002","journal-title":"Oncol. Lett."},{"key":"4333_CR23","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1507\/endocrj.EJ20-0287","volume":"68","author":"S Ishihara","year":"2021","unstructured":"S. Ishihara, N. Onoda, S. Noda, Y. Tauchi, T. Morisaki, Y. Asano, S. Kashiwagi, T. Takashima, M. Ohira, Treatment of anaplastic thyroid cancer with tyrosine kinase inhibitors targeted on the tumor vasculature: initial experience in clinical practice. Endocr. J. 68, 63\u201368 (2021)","journal-title":"Endocr. J."},{"key":"4333_CR24","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2022.06.044","volume":"173","author":"T Higashiyama","year":"2022","unstructured":"T. Higashiyama, K. Sugino, H. Hara, K.I. Ito, N. Nakashima, N. Onoda, M. Tori, H. Katoh, N. Kiyota, I. Ota, N. Suganuma, Y. Hibi, T. Nemoto, S. Takahashi, K. Yane, T. Ioji, S. Kojima, H. Kaneda, I. Sugitani, M. Tahara, Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE). Eur. J. Cancer 173, 210\u2013218 (2022)","journal-title":"Eur. J. Cancer"},{"key":"4333_CR25","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1001\/jamaoncol.2020.3362","volume":"6","author":"A Maniakas","year":"2020","unstructured":"A. Maniakas, R. Dadu, N.L. Busaidy, J.R. Wang, R. Ferrarotto, C. Lu, M.D. Williams, G.B. Gunn, M.C. Hofmann, G. Cote, J. Sperling, N.D. Gross, E.M. Sturgis, R.P. Goepfert, S.Y. Lai, M.E. Cabanillas, M. Zafereo, Evaluation of overall survival in patients with anaplastic thyroid carcinoma, 2000\u20132019. JAMA Oncol. 6, 1397\u20131404 (2020)","journal-title":"JAMA Oncol."},{"key":"4333_CR26","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1089\/thy.2019.0477","volume":"30","author":"D Dias-Santagata","year":"2020","unstructured":"D. Dias-Santagata, J.K. Lennerz, P.M. Sadow, R.P. Frazier, S. Govinda Raju, D. Henry, T. Chung, J. Kherani, S.M. Rothenberg, L.J. Wirth, Response to RET-specific therapy in RET fusion-positive anaplastic thyroid carcinoma. Thyroid 30, 1384\u20131389 (2020)","journal-title":"Thyroid"},{"key":"4333_CR27","doi-asserted-by":"publisher","first-page":"bvae158","DOI":"10.1210\/jendso\/bvae158","volume":"8","author":"O Elghawy","year":"2024","unstructured":"O. Elghawy, A. Barsouk, A. Heidlauf, S. Chen, R.B. Cohen, L. Sun, Single-institution experience of larotrectinib therapy for patients with NTRK fusion-positive thyroid carcinoma. J. Endocr. Soc. 8, bvae158 (2024). https:\/\/doi.org\/10.1210\/jendso\/bvae158","journal-title":"J. Endocr. Soc."},{"key":"4333_CR28","doi-asserted-by":"publisher","first-page":"e220179","DOI":"10.1530\/ETJ-22-0179","volume":"12","author":"I Dam\u00e1sio","year":"2023","unstructured":"I. Dam\u00e1sio, J. Sim\u00f5es-Pereira, S. Donato, M. Horta, B.M. Cavaco, M. Rito, P. Gomes, V. Leite, Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report. Eur. Thyroid. J. 12, e220179 (2023). https:\/\/doi.org\/10.1530\/ETJ-22-0179","journal-title":"Eur. Thyroid. J."},{"key":"4333_CR29","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1210\/clinem\/dgab731","volume":"107","author":"MS Brose","year":"2022","unstructured":"M.S. Brose, Y. Panaseykin, B. Konda, C. de la Fouchardiere, B.G.M. Hughes, A.G. Gianoukakis, Y. Joo Park, I. Romanov, M.K. Krzyzanowska, S. Leboulleux, T.A. Binder, C. Dutcus, R. Xie, M.H. Taylor, A randomized study of lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 107, 776\u2013787 (2022)","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04333-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04333-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:00:25Z","timestamp":1758772825000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04333-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["4333"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04333-5","relation":{},"ISSN":["1559-0100"],"issn-type":[{"type":"electronic","value":"1559-0100"}],"subject":[],"published":{"date-parts":[[2025,6,28]]},"assertion":[{"value":"23 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the standards of the Declaration of Helsinki and current ethical guidelines. Approval was obtained from the Institutional Review Board and Research Ethics Committee of Keio University School of Medicine (reference number: 20190093).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained in the form of opt-out on the web-site and by information in the hospital.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and publish"}}]}}